Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma

This study is testing an immunotherapy drug called tislelizumab (a checkpoint inhibitor) given after liver-directed treatments (such as radiation or TACE) for patients with hepatocellular carcinoma (liver cancer). Researchers want to see if adding immunotherapy after local liver treatment improves outcomes. **You may be eligible if...** - You have been diagnosed with primary liver cancer (hepatocellular carcinoma) - You have not yet received systemic (whole-body) treatment for liver cancer - You do not have cancer that has spread outside the liver - You are 18 or older and in reasonably good health (ECOG 0–2) - Your liver function is acceptable (Child-Pugh A or B7) - You have measurable disease **You may NOT be eligible if...** - You have previously had immunotherapy - You have had a liver transplant - You are HIV positive - You have uncontrolled hepatitis B or C infection - You have significant fluid buildup in the abdomen (ascites requiring procedures) - You have had a heart attack, stroke, or heart failure in the past 6 months - You have a history of autoimmune lung disease - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.